08:08 AM EST, 02/20/2025 (MT Newswires) -- Aptose Biosciences ( APTO ) surged 48% in pre-market trading on Thursday after saying the Cohort Safety Review Committee (CSRC) monitoring Aptose's Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine has approved doubling the tuspetinib dosage to 80 mg.

The approval is based on the CSRC's favorable review of data from the first four patients in the trial. The triple therapy is being developed as a frontline therapy to treat large, mutationally diverse populations of newly diagnosed acute myeloid leukemia (AML) patients who are ineligible to receive induction chemotherapy.

All four subjects treated in the 40 mg cohort remain on study while enrollment is open for the 80 mg cohort.

Aptose was last seen up US$0.07, to US$0.22 in New York trading.